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Background: Flow-based, multiplex bead arrays (MBA) have been developed for a variety of
applications including the detection of antibodies to extractable nuclear antigens (ENA). It offers a
rapid and sensitive method to assess multiple analyses in a single tube/well.
Purpose: To evaluate the Athena Multi-Lyte ANA Test System utilizes Luminex Corporation’s
MBA technology for the detection of antinuclear antibodies (ANA) and ENA antibodies in the sera of
patients with Sjogren’s syndrome (SS).
Methods: MBA assay was used to detect ANA and ENA antibodies in the sera of 37 patients with SS
and 96 sera from healthy subjects.
Results: All patients were women. Their mean age was 48.7 years and the mean disease duration was
7.27 years. ANA was found in 3 (3%) sera of healthy subjects by the AtheNA system and in 2 (2%) sera
by the ELISA kit. A 99% concordance between the 2 assays was found. A 94.6% concordance between
the 2 assays was found by testing the sera of patients with SS for ANA.
By the AtheNA system, none of the sera of 37 patients with SS had autoantibodies reacting with Sm,
Jo-1, dsDNAor histones. Anti-RNPantibody was found in5.4%of the sera and2.7%of the sera reacted
with Scl-70 and histones. Anti-SS/A and anti-SS/B were identiﬁed in 84 and 76% of the sera,
respectively.
Conclusion: The AtheNa Multi-Lyte ANA Test System offers a sensitive and speciﬁc result for the
detection of ANA and ENA antibodies in the sera of patients with SS.
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Sjogren’s syndrome (SS) is an autoimmune disease with
distinct clinical and laboratory features. Cardinal features
of the disease include focal mononuclear cell inﬁltration
of exocrine tissues, the production of a wide variety of
autoantibodies, and oral and ocular symptoms and signs of
dryness (Fox et al., 2000). In addition, the patients with SS
may present with respiratory, cutaneous, musculoskeletal,
central nervous system, renal and other vital organs
involvement. Laboratory features of SS include hyper-
globulinemia, presence of: rheumatoid factor, antinuclear
antibodies (ANA), anti-SS/A and -SS/B autoantibodies
(Cervera et al., 2000).
Recently, ﬂow-based, multiplex bead arrays (MBA)
have been developed for a variety of applications
including the detection of extractable nuclear antigens
(ENA) antibodies. This platform offers the potential for
a rapid and sensitive method with reduced hands-on time
required for performance because of the ability to assess
multiple analytes in a single tube/well (Fulto et al., 1997;
Dario, 2000; Prabhakar et al., 2002; Rouquette et al.,
2003). AtheNA multi-lyte test system is a homogeneous,
multiplexed system for autoantibodies analysis. It is
precise and easy to use technology for simultaneous
quantitative multi-autoantibody detection in a single
microtiter well.
The purpose of this study was to evaluate the Athena
Multi-Lyte ANA Test; an MBA technology for the
detection of ANA and ENA antibodies in the sera of
patients with SS and healthy subjects. In addition to
determine the concordance between AtheNA and
standard ELISA assays in detecting of antinuclear
antibodies.
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Patients
The study population comprised of 37 consecutive
patients with SS. All patients fulﬁlled the criteria of
classiﬁcation of SS (Vitali et al., 2002). Patients were seen
at 3–4 months intervals.
Autoantibody Determination
AtheNA Multi-Lyte ANA Test System (Zeus Scientiﬁc,
Inc. Raritan, NJ 08869, USA) was used for simultaneous
determination of autoantibodies to nine different analyts
(SS/A, SS/B, Sm, RNP, Scl 70, Jo-1, dsDNA, Centromere
B and Histone).
ANA in sera of patients and control subjects was
evaluated by the AtheNA Multi-Lyte ANA Test System
and by AESKULISA ANA-8S ELISA assay (Aesku.lab
Diagnostika Mikroforum Ring 2 55234 Wendelsheim
Germany).
Positive tests for all individual autoantibodies in the
AtheNA Multi-Lyte ANA Test System were deﬁned as
values greater than 120units/ml (cutoff normal range). For
the ANA tests, values .1.2 were deﬁned as positive.
Controls
Sera of age matched apparently healthy women were
obtained from national blood bank and were also tested by
the AtheNA system for ANA and the various
autoantibodies.
Statistical Analyses
Statistical analysis was carried out using the STAT
program. Descriptive statistics and linear correlation were
used to correlate between the various assays.
RESULTS
The demographics and main clinical features of the
primary SS patients included in the study are shown in
Table I. All patients were women. Their mean age at
diagnosis of SS was 48.7 years (27–78) and their mean
disease duration was 7.27 years (1–15) from diagnosis
and 10.9 (range 3–23) from symptoms onset.
All patients had symptoms and objective signs of both
ocular and oral sicca syndrome. Other main clinical
features included are arthritis (28 patients, 76%), recurrent
parotid enlargement (15 patients, 41%), Raynaud’s
phenomenon (5 patients, 14%) and serositis (3 patients,
8%). None of the patients had malignancy, neurological,
cardiac or renal involvement.
Laboratory features included are leukopenia (17
patients, 46%), rheumatoid factor positivity (31 patients,
84%), hypergammaglobulinemia (21 patients, 57%) and
monoclonal gammopathy in 3 patients (8%).
Medical treatment given during the disease course are
shown in Table I.
Autoantibody Proﬁle
Normal Sera
The sera of 98 apparently normal individuals, obtained
from national blood bank were tested by the AtheNA
system and by AESKU Diagnostics ANA-8S ELISA Kit.
ANA was found in 3 (3%) sera from healthy subjects by
the AtheNA system and in 2 (2%) sera by the ELISA kit.
A 99% concordance between the 2 assays was found.
All sera were tested by the AtheNA for autoantibodies
reacting with: SS/A, SS/B, Sm, RNP, Scl-70, Jo-1,
dsDNA, Centromere and histones. None of the sera had
anti-SS/A, anti-SS/B, anti-Jo-1, anti-dsDNA, anti-centro-
mere or anti-histone activity.
Anti-Sm, anti-RNP and anti-Scl-70 were detected each
in one (1%) serum.
Sera of Patients with SS
Table II shows the percentage of patients with SS and
healthy controls who had ANA by the AtheNA system and
by the AESKU Diagnostics ANA-8S ELISA kit. A 94.7%
concordance between the 2 assays was found by testing
the sera of patients with SS.
TABLE I Demographics and clinical features of the patients with
Sjogren’s syndrome
Gender
Female(%) 100
Age
Years (range) 48.7 (27–78)
Disease duration years (range)
From symptoms onset 10.95 (3–23)
From diagnosis 7.27 (1–15)
Main clinical features
Ocular 37/37
Oral 37/37
Recurrent parotid enlargement 15/37
Arthritis/arthralgia 28/37
Serositis 3/37
Vasculitic purpura 2/37
Raynaud’s phenomenon 5/37
Autoimmune hepatitis 2/37
Autoimmune thyroiditis 3/37
Leucopenia (,4.000/mm
3) 17/37
Rheumatoid factor þ 31/37
Polyclonal 21/37
MGUS* 3/37
Neurological involvement 0/37
Drugs
Corticosteroids (5–7.5mg for less than 3 months)
Current 0/37
Previous 13/37
NSAIDs
Current 6/37
Previous 7/37
Hydroxychloroquine
Current 13/37
Previous 2/37
*Monoclonal gammopathies of unknown signiﬁcance.
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with SS had autoantibodies reacting with Sm, Jo-1,
dsDNA or histones. Anti-RNP antibody was found in
5.4% of the sera (2 patients) and 2.7% of the sera
(1 patient) reacted with Scl-70 and histones.
Anti-SS/A and -SS/B, which are highly associated with
SS, were identiﬁed in 84% (31 patients) and 76% of the
sera (28 patients), respectively. Their titers are shown
in Fig. 1.
DISCUSSION
During the last 3 decades a wide range of autoantibodies
has been identiﬁed in the sera of patients with various
autoimmune diseases. In a recent review, (Sherer et al.)
more than 100 autoantibodies reported in the sera of
patients with systemic lupus erythematosus (SLE).
A signiﬁcant number of those autoantibodies were found
to be pathogenic and has a diagnostic and/or activity role
in various autoimmune diseases (Cervera and Shoenfeld,
1996). In a substantial number of cases the diagnosis
of autoimmune disease is conﬁrmed by the detection of
speciﬁc autoantibodies. Therefore, rapid and sensitive
methods are needed to allow prompt identiﬁcation of
autoantibodies and early diagnosis of autoimmune
diseases.
Recently, ﬂow-based, MBA have been developed for
detectionofavarietyofautoantibodiesincludingANA,anti-
sdDNA, anti-ENA, anti-histones, antibodies reacting
with various ribo-nuclear proteins and other autoantibodies.
This system allows evaluating multiple autoantibodies
in a single tube or well (Rouquette et al., 2003).
In a recent study, the sera of patients with various
autoimmune rheumatic diseases were tested for 15
autoantibodies in microarrays. The data of the microarray
system were similar to those by conventional method
(Feng et al., 2003).
The AtheNA multi-lyte Test System was developed by
Zeus Scientiﬁc (Raritan, NJ). It is a homogeneous,
multiplexed system for autoantibodies analysis. It is
highly precise and easy to use technology for simul-
taneous quantitative multi-autoantibody detection in a
single microtiter well.
In the present study, we found a 99 and 94.7%
concordance between AtheNA and standard ELISA assay
for detection of ANA in the sera of apparently healthy
individuals and sera of patients with SS, respectively. The
data suggest that the AtheNA Multi-Lyte ANA Test
System offers a sensitive and speciﬁc instrument for the
detection of ANA in the sera of healthy individuals and
patients with an autoimmune disease.
In addition, the sera of the patients with SS and healthy
controls were also tested by AtheNA for a various
autoantigens including dsDNA, histones, RNP, Sm, SS/A,
SS/B, Jo-1 and centromere.
In the sera of the normal individuals, no autoantibody
activity was detected in the vast majority of sera. Only 3
individuals had autoantibodies in their sera. One
individual had anti-Sm, other one had anti-RNP and a
third person had anti-Scl-70, all of them were in low-
medium titers.
The presence of autoantibodies in the sera of normal
individuals in low-medium titers has been reported in
numerous reports. Usually, those autoantibodies are poly-
speciﬁc, belong to the IgM isotype, and bind their
autoantigens with low afﬁnity and avidity (Abu-Shakra
and Shoenfeld, 1993). All of these features are
characteristics of natural autoantibodies. The frequency
of autoantibodies in normal individuals ranges between
0.5 and 27% (Abu-Shakra and Shoenfeld, 1993).
The sera of the patients with SS reacted mainly with
SS/A and SS/B. Eighty-four and 74% of the sera of the SS
patients had medium-high titer of anti-SS/A and -SS/B
antibodies. A literature review has found the reported
frequency of anti-SS/A and anti-SS/B in the sera of
patients with SS to be between 50–90% (Bell et al., 1999;
Cervera and Shoenfeld, 1996).
FIGURE 1 Anti SS/A and anti-SS/B in the sera of patients with SS.
TABLE II Evaluation of ANA screening by AtheNA multiplex system
and standard ELISA kit
Group AtheNA No (%) ELISA No (%) Concordance (%)
Healthy controls
Positive 93 94 99
Negative 3 2
Patients with Sjorgen’s syndrome
Positive 32 30
Negative 5 7 94.6
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the highly precise technology of the AtheNA evaluation,
makes it feasible and easy to conduct the simultaneous
detection of quantitive multiple autoantibodies in a single
micro titer, in the sera of patients with SS and in the sera of
normal individuals.
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